|
US3647858A
(en)
|
1970-05-01 |
1972-03-07 |
Merck & Co Inc |
Process for preparing 1-benzylidene-3-indenyl acetic acids
|
|
US3654349A
(en)
|
1970-05-01 |
1972-04-04 |
Merck & Co Inc |
Substituted indenyl acetic acids
|
|
US4413141A
(en)
|
1977-07-11 |
1983-11-01 |
Merrell Toraude Et Compagnie |
2-(Difluoromethyl)-2,5-diaminopentanoic acid
|
|
US4309442A
(en)
|
1977-07-11 |
1982-01-05 |
Merrell Toraude Et Compagnie |
Method for controlling fertility in mammals
|
|
US4330559A
(en)
|
1977-07-11 |
1982-05-18 |
Merrell-Toraude Et Cie |
Method of treating benign prostatic hypertrophy
|
|
US4499072A
(en)
|
1982-11-29 |
1985-02-12 |
Merrell Dow Pharmaceuticals Inc. |
Process for treating diseases with ODC inhibitors
|
|
US4859452A
(en)
|
1986-01-17 |
1989-08-22 |
Board Of Regents, The University Of Texas System |
Methods for the reduction of difluoromethylornithine associated toxicity
|
|
US4925835A
(en)
|
1986-05-01 |
1990-05-15 |
Sloan-Kettering Institute For Cancer Research |
Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
|
|
US5002879A
(en)
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5801029A
(en)
|
1993-02-16 |
1998-09-01 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
FR2706255B1
(fr)
|
1993-06-17 |
1995-10-27 |
Univ Rennes |
Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
|
|
CA2144319A1
(en)
|
1993-07-09 |
1995-01-19 |
George N. Cox |
Recombinant ctla4 polypeptides and methods for making the same
|
|
US5456908A
(en)
|
1994-03-01 |
1995-10-10 |
The University Of Kentucky Research Foundation |
Polyamine-polyamine and polyamine-protein transport inhibitor conjugates and their use as pharmaceuticals and in research relating to polyamine transport
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US5843929A
(en)
|
1996-03-22 |
1998-12-01 |
Mayo Foundation For Medical Education And Research |
Chemoprevention of metachronous adenomatous colorectal polyps
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US6083496A
(en)
|
1996-10-22 |
2000-07-04 |
Universite Laval |
Polyamine transport inhibitors
|
|
WO1998019667A1
(en)
|
1996-11-01 |
1998-05-14 |
Ilex Oncology, Inc. |
Sustained release formulation containing dfmo
|
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
|
US6258845B1
(en)
|
1998-03-28 |
2001-07-10 |
The Regents Of The University Of California |
DFMO and sulindac combination in cancer chemoprevention
|
|
CA2304557C
(en)
|
1998-04-21 |
2008-12-30 |
Universite Laval |
Polyamine transport inhibitors
|
|
US7700568B2
(en)
|
1998-06-30 |
2010-04-20 |
Sloan-Kettering Institute For Cancer Research |
Uses of DNA-PK
|
|
EA006972B1
(ru)
|
1998-12-23 |
2006-06-30 |
Пфайзер Инк. |
Моноклональное антитело человека к ctla-4 и способы его применения
|
|
US6753422B2
(en)
|
1999-03-01 |
2004-06-22 |
O'brien Thomas G. |
Odc allelic analysis method for assessing carcinogenic susceptibility
|
|
AU5140300A
(en)
|
1999-05-17 |
2000-12-05 |
Ilex Oncology, Inc. |
Dfmo and celecoxib in combination for cancer chemoprevention and therapy
|
|
US6428809B1
(en)
|
1999-08-18 |
2002-08-06 |
Microdose Technologies, Inc. |
Metering and packaging of controlled release medication
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
WO2001068076A2
(en)
|
2000-03-07 |
2001-09-20 |
Ilex Oncology, Inc. |
D-enantiomer of dfmo and methods of use thereof for treating cancer
|
|
US6602910B2
(en)
|
2000-03-07 |
2003-08-05 |
Ilex Oncology, Inc. |
D-enantiomer of DFMO and methods of use therefor
|
|
AU2001285232A1
(en)
|
2000-08-24 |
2002-03-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Alpha-difluoromethylornithine (dfmo) use in the human prostate
|
|
AU2002343609B2
(en)
|
2001-11-16 |
2008-12-11 |
Als Therapy Development Foundation, Inc. |
Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
|
|
AU2003293180A1
(en)
|
2002-11-29 |
2004-06-23 |
Forest Laboratories Inc |
Combination of ibuprofen and oxycodone for acute pain relief
|
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
|
WO2007075673A1
(en)
|
2005-12-20 |
2007-07-05 |
University Of Hawaii |
Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
|
|
DK2043637T3
(da)
|
2006-07-18 |
2012-05-07 |
Horizon Pharma Usa Inc |
Fremgangsmåder og medikamenter til administrering af ibuprofen
|
|
AU2007333735A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
|
BRPI0812913B8
(pt)
|
2007-06-18 |
2021-05-25 |
Merck Sharp & Dohme |
anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
|
|
JP5765937B2
(ja)
|
2007-08-01 |
2015-08-19 |
シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ |
小児腫瘍の治療
|
|
WO2009048932A2
(en)
|
2007-10-09 |
2009-04-16 |
Children's Medical Center Corporation |
Methods to regulate mirna processing by targeting lin-28
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
MX2010014364A
(es)
|
2008-06-30 |
2011-08-12 |
Morphotek Inc |
Anticuerpos anti-gd2 y metodos y usos relacionados con los mismos.
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
CA2735006A1
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
MX2011002470A
(es)
|
2008-09-08 |
2011-04-05 |
Merck Patent Gmbh |
Pirimidinas macrociclicas como inhibidores de aurora cinasa.
|
|
US20100120727A1
(en)
*
|
2008-11-12 |
2010-05-13 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
|
|
BRPI0922379B1
(pt)
|
2008-12-08 |
2021-08-03 |
The Procter & Gamble Company |
Composição para cuidados pessoais na forma de um artigo que tem um revestimento hidrofóbico residente de superfície
|
|
PT2430452E
(pt)
|
2009-05-14 |
2014-09-30 |
Univ Arizona State |
Diagnóstico e tratamentos de carcinoma com base no genótipo odc1
|
|
US20120259013A1
(en)
|
2009-05-20 |
2012-10-11 |
Ranbaxy Laboratories Limited |
Liquid dosage forms of isotretinoin
|
|
US9212131B2
(en)
|
2009-06-19 |
2015-12-15 |
University Of Central Florida Research Foundation, Inc. |
Polyamine transport inhibitors as novel therapeutics
|
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
|
|
KR101926663B1
(ko)
|
2010-02-19 |
2018-12-07 |
젠코어 인코포레이티드 |
신규의 ＣＴＬＡ４-Ｉｇ 이뮤노어드헤신
|
|
US20110256161A1
(en)
|
2010-04-19 |
2011-10-20 |
Aminex Therapeutics Inc. |
Methods for enhancing immune response
|
|
WO2011135459A2
(en)
|
2010-04-29 |
2011-11-03 |
Medical Prognosis Institute A/S |
Methods and devices for predicting treatment efficacy
|
|
WO2011143579A2
(en)
|
2010-05-14 |
2011-11-17 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Cancer prevention and treatment methods based on dietary polyamine content
|
|
EP2582722A4
(en)
|
2010-06-19 |
2013-12-18 |
Sloan Kettering Inst Cancer |
ANTIBODIES AGAINST GD2
|
|
EP2614143B1
(en)
|
2010-09-08 |
2018-11-07 |
Baylor College Of Medicine |
Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
|
|
US9249124B2
(en)
|
2011-03-30 |
2016-02-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase inhibitors and methods of making and using thereof
|
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
LT2912193T
(lt)
|
2012-10-29 |
2018-12-27 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Prognozuojami žymenys, skirti vėžio terapijoms poliamino inhibitoriumi
|
|
GB2513299A
(en)
|
2013-03-12 |
2014-10-29 |
Cellact Pharma Gmbh Biomedizinzentrum |
Compounds for targeting cancer stem cells
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗ｇｄ２抗体
|
|
CA2917858A1
(en)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
ES2927567T3
(es)
|
2013-09-13 |
2022-11-08 |
Beigene Switzerland Gmbh |
Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
|
|
WO2015195120A1
(en)
|
2014-06-18 |
2015-12-23 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Carcinoma diagnosis and treatment based on odc1 genotype
|
|
WO2016130918A1
(en)
*
|
2015-02-12 |
2016-08-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods for treating neuroblastoma
|
|
WO2017075576A1
(en)
|
2015-10-30 |
2017-05-04 |
Cancer Prevention Pharmaceuticals, Inc. |
Eflornithine and sulindac, fixed dose combination formulation
|
|
BR112018008651A2
(pt)
*
|
2015-10-30 |
2018-10-30 |
Cancer Prevention Pharmaceuticals Inc |
formulação de combinação de dose fixa de eflornitina e sulindaco
|
|
JP2022532766A
(ja)
*
|
2019-05-17 |
2022-07-19 |
キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド |
家族性腺腫性ポリポーシスを処置するための方法
|